middle.news
Cleo Diagnostics Sets U.S. Reimbursement Stage Ahead of FDA Nod
10:00am on Thursday 1st of January, 1970 AEST
•
Healthcare
Read Story
Cleo Diagnostics Sets U.S. Reimbursement Stage Ahead of FDA Nod
10:00am on Thursday 1st of January, 1970 AEST
Key Points
U.S. market entry via CPT code 81599 post-FDA clearance
Reimbursement benchmarked at US$500–900 per test
Plan to secure dedicated CPT code for long-term scale
Strategy supports early revenue and real-world evidence
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE